In a research report issued Monday, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on shares of Neuralstem, Inc. (NYSE MKT:CUR), with an $8.00 price target, following the company’s first-quarter financial results and update on its pipeline.
Aschoff noted, “We believe that at the current valuation, there is almost nothing for any NSI-566 program, and thus that interest in the ALS program will increase once the comprehensive results are presented by a KOL, and thus view the current valuation as quite conservative.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jonathan Aschoff has a total average return of 6.3% and a 52.9% success rate. Aschoff has a -36.3% average return when recommending CUR, and is ranked #570 out of 3596 analysts.
Out of the 5 analysts polled by TipRanks, three rate Neuralstem stock a Buy, one rate the stock a Hold and one recommend a Sell. With a return potential of 125.28%, the stock’s 12-month consensus target price stands at $4.13.